Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Stocks · News reference
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47
Piper Sandler analyst David Westenberg maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $42 to $47.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Capital Initiates Coverage On 10x Genomics with Sector Perform Rating, Announces Price Target of $70
RBC Capital analyst Dan Leonard initiates coverage on 10x Genomics (NASDAQ:TXG) with a Sector Perform rating and announces Price Target of $70.
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences
10x Genomics secured a favorable jury verdict against Parse Biosciences (a Qiagen subsidiary), winning $4.8M in damages for willful patent infringement on three single-cell analysis patents. The jury upheld all three patents' validity. 10x Genomics plans to seek enhanced damages, attorney fees, and a permanent U.S. injunction in post-trial proceedings. Despite the legal win, TXG shares fell over 5% following the announcement.
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit
10x Genomics won a $4.8 million patent infringement lawsuit against Qiagen subsidiary Parse Biosciences, prompting plans for an injunction.